Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

410 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Phase II Study With Epirubicin, Cisplatin, and Infusional Fluorouracil Followed by Weekly Paclitaxel With Metronomic Cyclophosphamide as a Preoperative Treatment of Triple-Negative Breast Cancer.
Cancello G, Bagnardi V, Sangalli C, Montagna E, Dellapasqua S, Sporchia A, Iorfida M, Viale G, Barberis M, Veronesi P, Luini A, Intra M, Goldhirsch A, Colleoni M. Cancello G, et al. Among authors: barberis m. Clin Breast Cancer. 2015 Aug;15(4):259-65. doi: 10.1016/j.clbc.2015.03.002. Epub 2015 Mar 18. Clin Breast Cancer. 2015. PMID: 25933934 Clinical Trial.
Prevalence and clinicopathologic correlates of O⁶-methylguanine-DNA methyltransferase methylation status in patients with triple-negative breast cancer treated preoperatively by alkylating drugs.
Fumagalli C, Della Pasqua S, Bagnardi V, Cardillo A, Sporchia A, Colleoni M, Viale G, Barberis M, Pruneri G. Fumagalli C, et al. Among authors: barberis m. Clin Breast Cancer. 2014 Aug;14(4):285-90. doi: 10.1016/j.clbc.2014.02.010. Epub 2014 Mar 2. Clin Breast Cancer. 2014. PMID: 24709436
Sensitive and affordable diagnostic assay for the quantitative detection of anaplastic lymphoma kinase (ALK) alterations in patients with non-small cell lung cancer.
Dama E, Tillhon M, Bertalot G, de Santis F, Troglio F, Pessina S, Passaro A, Pece S, de Marinis F, Dell'Orto P, Viale G, Spaggiari L, Di Fiore PP, Bianchi F, Barberis M, Vecchi M. Dama E, et al. Among authors: barberis m. Oncotarget. 2016 Jun 14;7(24):37160-37176. doi: 10.18632/oncotarget.9471. Oncotarget. 2016. PMID: 27206799 Free PMC article.
An Aggressive Subtype of Stage I Lung Adenocarcinoma with Molecular and Prognostic Characteristics Typical of Advanced Lung Cancers.
Dama E, Melocchi V, Dezi F, Pirroni S, Carletti RM, Brambilla D, Bertalot G, Casiraghi M, Maisonneuve P, Barberis M, Viale G, Vecchi M, Spaggiari L, Bianchi F, Di Fiore PP. Dama E, et al. Among authors: barberis m. Clin Cancer Res. 2017 Jan 1;23(1):62-72. doi: 10.1158/1078-0432.CCR-15-3005. Epub 2016 Jun 29. Clin Cancer Res. 2017. PMID: 27358486
The long tail of molecular alterations in non-small cell lung cancer: a single-institution experience of next-generation sequencing in clinical molecular diagnostics.
Fumagalli C, Vacirca D, Rappa A, Passaro A, Guarize J, Rafaniello Raviele P, de Marinis F, Spaggiari L, Casadio C, Viale G, Barberis M, Guerini-Rocco E. Fumagalli C, et al. Among authors: barberis m. J Clin Pathol. 2018 Sep;71(9):767-773. doi: 10.1136/jclinpath-2018-205032. Epub 2018 Mar 13. J Clin Pathol. 2018. PMID: 29535211
Mutational analysis of triple-negative breast cancers within the International Breast Cancer Study Group (IBCSG) Trial 22-00.
Munzone E, Gray KP, Fumagalli C, Guerini-Rocco E, Láng I, Ruhstaller T, Gianni L, Kammler R, Viale G, Di Leo A, Coates AS, Gelber RD, Regan MM, Goldhirsch A, Barberis M, Colleoni M. Munzone E, et al. Among authors: barberis m. Breast Cancer Res Treat. 2018 Jul;170(2):351-360. doi: 10.1007/s10549-018-4767-1. Epub 2018 Mar 27. Breast Cancer Res Treat. 2018. PMID: 29589138 Clinical Trial.
410 results